Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Key value for chemical safety assessment

Genetic toxicity in vitro

Description of key information
Using all available data and with an weight of evidence approach it is considered that the substance has no potential for genetic toxicity.
Link to relevant study records

Referenceopen allclose all

Endpoint:
genetic toxicity in vitro, other
Type of information:
(Q)SAR
Adequacy of study:
weight of evidence
Reliability:
4 (not assignable)
Rationale for reliability incl. deficiencies:
other: The predicted compound is outside the Applicability Domain of the model
Justification for type of information:
QSAR prediction
Principles of method if other than guideline:
Mutagenicity (Ames test) model (CAESAR) 2.1.13
Mutagenicity (Ames test) model (SarPy/IRFMN) 1.0.7
Mutagenicity (Ames test) model (ISS) 1.0.2
Mutagenicity (Ames test) model (KNN/Read-Across) 1.0.0
GLP compliance:
no
Remarks:
not applicable
Type of assay:
other: QSAR
Species / strain:
other: not applicable
Metabolic activation:
not applicable
Genotoxicity:
negative
Cytotoxicity / choice of top concentrations:
other: not applicable
Vehicle controls validity:
not applicable
Untreated negative controls validity:
not applicable
Positive controls validity:
not applicable
Remarks on result:
no mutagenic potential (based on QSAR/QSPR prediction)
Conclusions:
Interpretation of results: negative

With the models (CAESAR) 2.1.13, (ISS) 1.0.2 and (KNN/Read-Across) 1.0.0 the mutagen activity of the substance was predicted as non-mutagen. With the model (SarPy/IRFMN) 1.0.7 the mutagen activity of the substance was predicted as possible non-mutagen.
Endpoint:
genetic toxicity in vitro, other
Remarks:
Type of genotoxicity: gene mutation
Type of information:
(Q)SAR
Adequacy of study:
weight of evidence
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Model considered reliable by OECD
Justification for type of information:
QSAR prediction
Qualifier:
according to guideline
Guideline:
other: Guidance Document on the Validation of (Quantitative) Structure-Activity relationship models (OECD, 2007) and Guidance on Information Requirements and Chemical Safety Assessment/Chapter R.6: QSARS and Grouping Chemicals (ECHA, 2008)
Principles of method if other than guideline:
Read-across from category members
GLP compliance:
no
Remarks:
not applicable
Type of assay:
other: QSAR
Species / strain:
other: not applicable
Metabolic activation:
not applicable
Genotoxicity:
negative
Cytotoxicity / choice of top concentrations:
other: not applicable
Vehicle controls validity:
not applicable
Untreated negative controls validity:
not applicable
Positive controls validity:
not applicable
Remarks on result:
no mutagenic potential (based on QSAR/QSPR prediction)
Conclusions:
Interpretation of results: negative
Executive summary:

The read-across models predict this material is not mutagenic in salmonella typhimurium reverse

mutagenic (Ames) testing.

Endpoint:
genetic toxicity in vitro, other
Type of information:
(Q)SAR
Adequacy of study:
weight of evidence
Reliability:
4 (not assignable)
Rationale for reliability incl. deficiencies:
other: The official QMRF and QPRF formats were not met
Justification for type of information:
QSAR prediction
Principles of method if other than guideline:
Consensus method
GLP compliance:
no
Remarks:
not applicable
Type of assay:
other: QSAR
Species / strain:
other: not applicable
Metabolic activation:
not applicable
Genotoxicity:
negative
Cytotoxicity / choice of top concentrations:
other: not applicable
Vehicle controls validity:
not applicable
Untreated negative controls validity:
not applicable
Positive controls validity:
not applicable
Remarks on result:
no mutagenic potential (based on QSAR/QSPR prediction)
Conclusions:
Interpretation of results: negative

Mutagenicity Negative
Endpoint:
in vitro cytogenicity / chromosome aberration study in mammalian cells
Remarks:
Type of genotoxicity: chromosome aberration
Type of information:
experimental study
Adequacy of study:
weight of evidence
Study period:
28 April 1997 to 28 July 1997
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: The study was conducted according to GLP. Cytotoxicity was only evaluated during a range finding study.
Qualifier:
according to guideline
Guideline:
other: (Kanpogyo Notification No. 39, Yakuhatsu Notification No. 229, jointly issued with 59 Kikyoku Notification No. 85
Deviations:
not specified
Qualifier:
according to guideline
Guideline:
other: About Standard for Investigation by Chromosome Aberration Test using Cultured Mammalian Cells”(Kihatsu No. 143 issued by the director general of Ministry of Labor’s Labor Standards Bureau on March 18, 1987
Deviations:
not specified
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
GLP compliance:
yes
Type of assay:
in vitro mammalian chromosome aberration test
Species / strain / cell type:
mammalian cell line, other: The fibroblast cell line, CHL/IU, derived from the lungs of newborn female Chinese hamsters.
Details on mammalian cell type (if applicable):
- Type and identity of media:
- Properly maintained: yes
- Periodically checked for Mycoplasma contamination: Not reported
- Periodically checked for karyotype stability: Not reported
- Periodically "cleansed" against high spontaneous background: yes
Additional strain / cell type characteristics:
not specified
Metabolic activation:
with and without
Metabolic activation system:
S9
Test concentrations with justification for top dose:
The presence or absence of structural and numerical aberrations was determined at 12.5, 25, 50, and 100 µg/ml in the absence of metabolic
activation with the treatment periods of 24 and 48 hrs, at 44.4, 66.7, 100, and 150 µg/ml in the presence of metabolic activation without S9 Mix, and
at 444, 667, 1,000, and 1,500 µg/ml in the presence of metabolic activation with S9 Mix.
Vehicle / solvent:
- Vehicle(s)/solvent(s) used: physiological saline and DMSO
- Justification for choice of vehicle: solubility
Untreated negative controls:
yes
Remarks:
Physiological saline
Positive controls:
yes
Positive control substance:
mitomycin C
Remarks:
Migrated to IUCLID6: MMC; Lot Number ESH5706; biochemical grade
Positive controls:
yes
Positive control substance:
benzo(a)pyrene
Remarks:
Migrated to IUCLID6: Lot No. ECF6942; purity, 98%; analytical grade
Details on test system and experimental conditions:
METHOD OF APPLICATION: agar plate (plating method)

DURATION
- Preincubation period: not applicable
- Exposure duration:
Dose-ranging: 24 and 48 hours (direct method), 24 hours (metabolic activation method)
Main study: 24 and 48 hours (direct method), 6 hours (metabolic activation method)

- Expression time (cells in growth medium): 72 hours
- Selection time (if incubation with a selection agent): not applicable
- Fixation time (start of exposure up to fixation or harvest of cells):

Dose-ranging: 24 and 48 hours (direct method), 24 hours (metabolic activation method)
Main study: 24 and 48 hours (direct method), 24 hours (metabolic activation method)


SELECTION AGENT (mutation assays): not used
SPINDLE INHIBITOR (cytogenetic assays): Colcemid
STAIN (for cytogenetic assays): 3.0% Giemsa stain


NUMBER OF REPLICATIONS: 2


NUMBER OF CELLS EVALUATED: 100 per replicate


DETERMINATION OF CYTOTOXICITY
- Method: mitotic index; cloning efficiency; relative total growth; other: growth inhibition

OTHER EXAMINATIONS:
- Determination of polyploidy: Structural aberrations were classified into chromatid and chromosome gaps (gaps), chromatid break (ctb),
chromatid exchange (cte), chromosome break (csb), chromosome exchange (cse), and others (o) according to the Chromosomal Aberration Atlas6).
- Determination of endoreplication:
- Other:


OTHER:
Statistics:
The incidence of cells with chromosomal aberrations at each dose was analyzed and compared between the negative control group and each test
substance group by the ¿2-test. If significant differences were found, the binominal test was conducted between the background data from the
negative control group and data from each test substance group. If significant differences were observed, Cochran-Armitage’s trend test was
conducted to determine the presence or absence of dose-dependency. The test result was judged to be positive if all these tests showed significant
differences. Otherwise, the test result was regarded as negative. The D20 value was calculated if the test result was positive. Data obtained from
the positive control group were subjected to the ¿2-test and binominal test, and the test result was regarded as positive if both tests showed
significant differences.
Species / strain:
other: The fibroblast cell line, CHL/IU, derived from the lungs of newborn female Chinese hamsters.
Metabolic activation:
without
Genotoxicity:
ambiguous
Cytotoxicity / choice of top concentrations:
not determined
Untreated negative controls validity:
valid
Positive controls validity:
valid
Species / strain:
other: The fibroblast cell line, CHL/IU, derived from the lungs of newborn female Chinese hamsters.
Metabolic activation:
with
Genotoxicity:
ambiguous
Cytotoxicity / choice of top concentrations:
not determined
Untreated negative controls validity:
valid
Positive controls validity:
valid
Additional information on results:
TEST-SPECIFIC CONFOUNDING FACTORS
- Effects of pH: Not reported
- Effects of osmolality: Not reported
- Evaporation from medium: Not reported
- Water solubility:
- Precipitation:
- Other confounding effects:


RANGE-FINDING/SCREENING STUDIES:
A dose-ranging study was undertaken according to the testing guidelines in the presence of metabolic activation (using S9 Mix with a treatment
period of 6 hrs and a recovery period of 18 hrs and without using S9 Mix) and the absence of metabolic activation (with a treatment period of 24 or 48hrs) in order to select doses of the test substance for the main study by determining whether or not cell growth was inhibited2)3). The highest dose of the test substance was set at 5,000 µg/mL, followed by 1,500, 500, 150, 50, 15, and 5 µg/mL with a common ratio of about 3. The test
substance and negative control (physiological saline (JP) used as solvent) were used.

The results of the range finding study are tabulated in the "Any other information on results incl. tables" section below.


Dose-range finding test results

Direct method

24-hr

treatment

Dose (µg/mL)

0

5

15

50

150

500

1,500

5,000

Cell growth (%)*

100

102.5

84

40

12

0

0

0

48-hr treatment

Dose (µg/mL)

0

5

15

50

150

500

1,500

5,000

Cell growth (%)*

100

82

76

35

7

0

0

0

Metabolic activation method

Without S9 Mix

Dose (µg/mL)

0

5

15

50

150

500

1,500

5,000

Cell growth (%)*

100

118

112

74

21

0

0

0

With S9Mix

Dose (µg/mL)

0

5

15

50

150

500

1,500

5,000

Cell growth (%)*

100

99

96.5

94

91

64

17

0

* mean of two dishes Direct method (without metabolic activation): In the test conducted with a treatment period of 24 hrs, the incidence of cells with structural aberrations in the MODA groups was significantly and dose-dependently higher than in the negative control group: 20.0% at 50 µg/mL and 35.0% at 100 µg/mL compared to 2.0% in the negative control group. Significant, dose-dependent increases were also noted when the treatment period was extended to 48hrs: 7.5% at 50 µg/mL and 52.5% at 100 µg/mL compared to 1.5% in the negative control group. Chromatid breaks (ctb) and chromatid exchanges (cte) were the main structural aberrations regardless of the treatment period (24 or 48 hrs). The incidence of cells with numerical aberrations was similar in the test substance and negative control groups: 0.5-2.0% vs 0.0% for the treatment period of 24 hrs and 0.5-3.0% vs 0.5% for the treatment period of 48 hrs. In addition, the incidence of C-mitoses, which were not counted as aberrations but which are thought to contribute to the inhibition of the spindle formation, was 38.5% and 14.0%, respectively, when cells were treated for 24 and 48 hrs in the highest dose group (100 µg/mL). The D20 value for cells with structural aberrations was calculated to be 59.1 and 50.8 µg/mL, respectively, when cells were treated for 24 and 48 hrs. Cells with structural aberrations showed significant increases in the incidence in the positive control group treated with 0.05 µg/mL of MMC: 35.5% and 45.5%, respectively, when cells were treated for 24 and 48 hrs. The incidence of cells with numerical aberrations was 0.5% and 0.0%, respectively, when cells were treated for 24 and 48 hrs. Metabolic activation method: The incidence of cells with structural aberrations in the MODA groups increased significantly and dose-dependently compared to the negative control group (1.5%) when S9 Mix was not added with the incidence being 12.5% at 44.4 µg/mL, 23.5% at 66.7µg/mL, 28.5% at 100µg/mL and 44.5% at 150µg/mL. When S9 Mix was not added, however, the incidence of cells with structural aberrations was 2.0-3.5%, and no significant differences were noted compared to the negative control group (1.0%). No metaphase chromosomes were observed at the highest dose group (1,500 µg/mL) when S9 Mix was added. The incidence of cells with numerical aberrations increased significantly and dose-dependently at 44.4 µg/mL (4.5%), 66.7µg/mL (6.0%), and 100µg/mL (7.0%) when S9 Mix was not added, but it decreased to 2.5% at 150 µg/mL. The trend test was conducted up to 100 µg/mL because the cell growth rate was 21% at 150 µg/mL in the dose-ranging study, suggesting the presence of marked cytotoxicity at this and higher concentrations. The incidence of cells with numerical aberrations significantly increased to 5.5% at 1,000 µg/mL when S9 Mix was added. When S9 Mix was not added, the incidence of C-mitoses, which were not regarded as aberrant but were regarded as a factor that contributes to the inhibition of spindle formation, was 15.0% at 100 µg/mL and 31.5% at 150 µg/mL. The D20 value for cells with structural aberrations was 64.9 µg/mL when S9 Mix was not added. The incidence of cells with structural aberrations was 1.5% in the positive control group (B(a)P 20 µg/mL) when S9 Mix was not added, but it increased significantly to 36.0% when S9 Mix was added. The incidence of cells with numerical aberrations was 0.5% regardless of whether or nor S9 Mix was added.
Conclusions:
Interpretation of results:
positive with metabolic activation
positive without metabolic activation

It was concluded that MODA inhibited cell division regardless of the presence or absence of S9 Mix and induced structural chromosomal aberrations in the absence of S9 Mix under the conditions of the present study. The responses were generated at highly cytotoxic doses and should be interpreted with caution. Therefore a new in vitro micronucleus study (OECD 487, 2015) was conducted with the aim to evaluate the genotoxicity in an appropriate concentration range and with the determination of the cytotoxicity simultaneously during the main study.
Executive summary:
A study was conducted at Shin Nippon Biomedical Laboratories, Ltd, Japan, in order to evaluate whether or not the substance 2-methyl-1,8-octanediamine (MODA) induces chromosomal aberrations for the Chinese hamster's lung-derived fibroblast cell line CHL/IU. The study was conducted to GLP and according to the Japenese Guidelines 'Kanpogyo Notification No. 39, Yakuhatsu Notification No. 229, jointly issued with 59 Kikyoku Notification No. 85' and to 'Kihatsu No. 143'. The presence or absence of structural and numerical aberrations was determined at 12.5, 25, 50, and 100 µg/mL in the absence of metabolic activation with the treatment periods of 24 and 48 hrs, at 44.4, 66.7, 100, and 150 µg/mL in the presence of metabolic activation without S9 Mix, and at 444, 667, 1,000, and 1,500 µg/mL in the presence of metabolic activation with S9 Mix. The incidence of cells with structural aberrations significantly increased compared with the negative control in the absence of metabolic activation with the treatment periods of 24 and 48 hrs, as well as in the presence of metabolic activation without S9 Mix. The incidence of cells with numerical aberrations significantly increased compared to the negative control at 44.4-100 µg/mL in the presence of metabolic activation without S9 Mix and at 1,000 µg/mL in the presence of metabolic activation with S9 Mix. In addition, C-mitoses, which are not considered as aberrations but are thought to be due to the inhibition of spindle formation, were observed in high dose groups in the absence of metabolic activation and mid to high dose groups in the presence of metabolic activation without S9 Mix. The incidence of cells with structural and numerical aberrations in the negative and positive control groups was within the standard ranges of this laboratory. From these findings, it was concluded that MODA inhibited cell division regardless of the presence or absence of S9 Mix and induced structural chromosomal aberrations in the absence of S9 Mix under the conditions of the present study.
Endpoint:
in vitro gene mutation study in mammalian cells
Remarks:
Type of genotoxicity: gene mutation
Type of information:
experimental study
Adequacy of study:
weight of evidence
Study period:
2012
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
other: GLP guideline study
Qualifier:
according to guideline
Guideline:
OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)
GLP compliance:
yes (incl. QA statement)
Type of assay:
mammalian cell gene mutation assay
Target gene:
Thymidine Kinase (TK)
Species / strain / cell type:
mouse lymphoma L5178Y cells
Details on mammalian cell type (if applicable):
- Type and identity of media: complete growth medium F10P [Dulbecco’s modified Eagle’s Medium (DMEM) with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L glucose supplied with 0.1 % Pluronic, 90 % and Fetal bovine serum, 1 0%]. Treatment medium F5P [Dulbecco’s modified Eagle’s Medium (DMEM) with 4 mM Lglutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L glucose supplied with 0.1 % Pluronic, 95 % and Fetal bovine serum, 5 %].
Metabolic activation:
with and without
Metabolic activation system:
A co-factor supplemented postmitochondrial fraction (S9) from the liver of Aroclor 1254 induced Sprague- Dawley rats.
Test concentrations with justification for top dose:
2.5 µg/ml, 1.25 µg/ml, 0.625 µg/ml and 0.3125 µg/ml
Vehicle / solvent:
none
Untreated negative controls:
yes
Remarks:
sterile distilled water
Negative solvent / vehicle controls:
no
Positive controls:
yes
Positive control substance:
benzo(a)pyrene
methylmethanesulfonate
Details on test system and experimental conditions:
METHOD OF APPLICATION: in medium

DURATION
- Exposure duration: 4 hours
- Expression time (cells in growth medium): 48 hours
- Selection time (if incubation with a selection agent): 13 days

SELECTION AGENT (mutation assays): Trifluorothymidine (TFT)

NUMBER OF REPLICATIONS: 3

NUMBER OF CELLS EVALUATED: 3 x 10e6

DETERMINATION OF CYTOTOXICITY
- Method: relative total growth
Species / strain:
mouse lymphoma L5178Y cells
Metabolic activation:
with and without
Genotoxicity:
negative
Cytotoxicity / choice of top concentrations:
no cytotoxicity nor precipitates, but tested up to recommended limit concentrations
Remarks:
Cytotoxic effect of cell growth inhibition was observed at 2.5 µg/ml and above.
Untreated negative controls validity:
valid
Positive controls validity:
valid
Additional information on results:
TEST-SPECIFIC CONFOUNDING FACTORS
- Effects of pH: high pH values (pH 11.31 (0.6 mg/mL-water); pH 11.72 (3 mg/mL-water); pH 12.10 (15 mg/mL-water)) result in cytotoxicity
- Precipitation: none

RANGE-FINDING/SCREENING STUDIES: The testing concentrations of the test substances for the study were selected based on the results of preliminary range-finding test using L5178Y/TK+/- mouse lymphoma cells. In the range-finding test, cytotoxic effect of cell growth inhibition was observed at 2.5 µg/ml and above.
Conclusions:
Interpretation of results: negative

From the above study, the test item- methyl-1,8-octanediamine (MODA) is non-mutagenic to the L5178Y TK+/- clone, both in the absence and presence of S9 metabolic activation system.
Endpoint:
in vitro gene mutation study in bacteria
Remarks:
Type of genotoxicity: gene mutation
Type of information:
experimental study
Adequacy of study:
weight of evidence
Study period:
28 April 1997 to 14 July 1997
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
other: Guideline study conducted according to the principles of GLP.
Qualifier:
according to guideline
Guideline:
other: the Chemical Substances Control Law Test Guidelines (“Amendments of the ‘Test Methods for New Chemical Substances’”) (Kanpogyo Notification No. 700, Yakuhatsu Notification No. 1039; issued jointly with 61 Kikyoku Notification No. 1014
Deviations:
not specified
Qualifier:
according to guideline
Guideline:
other: Industrial Safety and Health Act Test Guidelines (Criteria Determined by the Ministry of Labor in Accordance with Paragraph 1, Article 57-2 of the Industrial Safety and Health Law (Act No. 57 of 1972) (Ministry of Labor Notice No. 77 of September 1, 1988)
Deviations:
not specified
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 471 (Bacterial Reverse Mutation Assay)
GLP compliance:
yes
Type of assay:
bacterial gene mutation assay
Target gene:
Not reported
Species / strain / cell type:
S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
Species / strain / cell type:
E. coli WP2 uvr A
Metabolic activation:
with and without
Metabolic activation system:
S9
Test concentrations with justification for top dose:
Based on the findings of a dose ranging study, the test substance concentrations were set at 156, 313, 625, 1250, 2500 and 5000 µg/plate both in
the presence and absence of metabolic activation.
Vehicle / solvent:
- Vehicle(s)/solvent(s) used: water for injection (batch No. 6C73N; supplied by Otsuka Pharmaceutical Factory Inc.)
- Justification for choice of solvent/vehicle: solubility
Untreated negative controls:
yes
Remarks:
water for injection
Positive controls:
yes
Positive control substance:
furylfuramide
Remarks:
(Lot No.: SAJ0748; purity: 99.4%; analytical grade; Wako Pure Chemical Industries, Ltd.)
Positive controls:
yes
Positive control substance:
N-ethyl-N-nitro-N-nitrosoguanidine
Remarks:
(Lot No.: V1A8648; purity: 97%; analytical grade; Nacalai Tesque, Inc.)
Positive controls:
yes
Positive control substance:
9-aminoacridine
Remarks:
(Lot No.: M0T3555; purity: 95%; analytical grade; Nacalai Tesque, Inc.)
Positive controls:
yes
Positive control substance:
other: 2-Aminoanthracene
Remarks:
(Lot No.: DSR3205; purity: 92.6%; analytical grade; Wako Pure Chemical Industries, Ltd.)
Details on test system and experimental conditions:
METHOD OF APPLICATION: in agar (plate incorporation)

DURATION
- Preincubation period: 12 hours (pre-culture)
- Exposure duration: 48 hours
- Expression time (cells in growth medium): not applicable
- Selection time (if incubation with a selection agent): not applicable
- Fixation time (start of exposure up to fixation or harvest of cells): not applicable


SELECTION AGENT (mutation assays): not applicable
SPINDLE INHIBITOR (cytogenetic assays): not applicable
STAIN (for cytogenetic assays): not applicable


NUMBER OF REPLICATIONS: not applicable


NUMBER OF CELLS EVALUATED: not applicable


DETERMINATION OF CYTOTOXICITY
- Method: mitotic index; cloning efficiency; relative total growth; other: growth inhibition


OTHER EXAMINATIONS:
- Determination of polyploidy: not applicable
- Determination of endoreplication: not applicable
- Other: not applicable


Evaluation criteria:
The test substance was regarded as mutagenic if the (mean) revertant colony count per plate showed 2-folds or greater increases compared to the
negative control, if these increases were dose-dependent, and if reproducibility is noted in the dose-ranging study and the main study. Otherwise,
the test substance was considered to be non-mutagenic.
Statistics:
No statistical analysis was conducted in the present study.
Key result
Species / strain:
S. typhimurium TA 1535
Metabolic activation:
with and without
Genotoxicity:
negative
Cytotoxicity / choice of top concentrations:
cytotoxicity
Remarks:
at 2,500 - 5,000 µg/plate
Untreated negative controls validity:
valid
Positive controls validity:
valid
Key result
Species / strain:
S. typhimurium TA 1537
Metabolic activation:
with and without
Genotoxicity:
negative
Cytotoxicity / choice of top concentrations:
cytotoxicity
Remarks:
at 2,500 - 5,000 µg/plate
Untreated negative controls validity:
valid
Positive controls validity:
valid
Key result
Species / strain:
S. typhimurium TA 98
Metabolic activation:
with and without
Genotoxicity:
negative
Cytotoxicity / choice of top concentrations:
cytotoxicity
Remarks:
at 2,500 - 5,000 µg/plate
Untreated negative controls validity:
valid
Positive controls validity:
valid
Key result
Species / strain:
S. typhimurium TA 100
Metabolic activation:
with and without
Genotoxicity:
negative
Cytotoxicity / choice of top concentrations:
cytotoxicity
Remarks:
at 2,500 - 5,000 µg/plate
Untreated negative controls validity:
valid
Positive controls validity:
valid
Key result
Species / strain:
E. coli WP2 uvr A
Metabolic activation:
with and without
Genotoxicity:
negative
Cytotoxicity / choice of top concentrations:
cytotoxicity
Remarks:
at 5000 µg/plate
Untreated negative controls validity:
valid
Positive controls validity:
valid
Additional information on results:
TEST-SPECIFIC CONFOUNDING FACTORS
- Effects of pH: Not reported
- Effects of osmolality: Not reported
- Evaporation from medium: Not reported
- Water solubility: Not reported
- Precipitation: The test substance did not precipitate up to 5000 µg/plate regardless of the presence or absence of metabolic activation.
- Other confounding effects: None


RANGE-FINDING/SCREENING STUDIES:
Negative with and without metabolic activation


COMPARISON WITH HISTORICAL CONTROL DATA:
In both the dose-ranging study and the main study, revertant colony counts noted in the negative and positive control groups were within the normalrange

ADDITIONAL INFORMATION ON CYTOTOXICITY: None

MODA did not cause 2-folds or greater increases in the revertant colony count for any of the five strains compared to the negative control regardless of the presence or absence of metabolic activation in either the dose-ranging study or the main study. The number of revertant colonies was within the reference range of this laboratory in both the negative control group and positive control groups, indicating that this study was conducted under appropriate conditions.

Table 1. Results of the Main Study

Metabolic activation

Concentration of test substance (µg/plate)

Revertant colony counts (per plate)

Base-pair substitution

Frame shift

TA100

TA1535

WP2uvrA

TA98

TA1537

S9 Mix

(-)

Negative control

(water for injection)

134, 136

(135)

10, 10

(10)

23, 17

(20)

17, 16

(17)

7, 10

(9)

156

142, 147

(145)

11, 7

(9)

22, 23

(23)

23, 21

(22)

6, 13

(10)

313

135, 125

(130)

16, 15

(16)

24, 27

(26)

28, 24

(26)

9, 12

(11)

625

134, 123

(129)

16, 13

(15)

22, 17

(20)

23, 17

(20)

4, 8

(6)

1250

138, 123

(131)

15, 13

(14)

26, 20

(23)

19, 28

(24)

10, 12

(11)

2500

83*, 97*

(90)

3*, 6*

(5)

23, 23

(23)

18, 16

(17)

5*, 4*

(5)

5000

0***, 0**

(0)

0**, 0**

(0)

13*, 15*

(14)

0**, 0**

(0)

0**, 0**

(0)

S9 Mix

(+)

Negative control

(water for injection

141, 150

(146)

11, 13

(12)

20, 20

(20)

38, 33

(36)

14, 10

(12)

156

127, 125

(126)

8, 10

(9)

18, 20

(19)

23, 34

(29)

9, 11

(10)

313

127, 124

(126)

7, 9

(8)

21, 18

(20)

34, 32

(33)

5, 7

(6)

625

138, 127

(133)

10, 13

(12)

20, 22

(21)

35, 31

(33)

7, 14

(11)

1250

128, 116

(122)

13, 14

(14)

31, 18

(25)

36, 30

(33)

12, 9

(11)

2500

96, 113

(105)

18, 11

(15)

26, 25

(26)

22, 33

(28)

13, 10

(12)

5000

57*, 64*

(61)

0**, 0**

(0)

15, 30

(23)

1*, 0**

(1)

4*, 5*

(5)

Positive control

Without S9 Mix

Name

AF-2

ENNG

ENNG

AF-2

9AA

Concentration (µg/plate)

0.01

5

2

0.1

80

Colony counts/plate

477, 432

(455)

187, 191

(189)

568, 537

(553)

685, 657

(671)

364, 458

(411)

With S9 Mix

Name

2AA

2AA

2AA

2AA

2AA

Concentration (µg/plate)

1

2

10

0.5

2

Colony counts/plate

1886, 1861

(1874)

445, 450

(448)

559, 514

(537)

934, 782

(858)

616, 550

(583)

(Remarks)

1. Figures in parentheses: means of two plates

2. Names of positive controls

AF-2: 2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide

ENNG: N-ethyl-N'-nitro-N-nitrosoguanidine

9AA: 9-aminoacridine

2AA: 2-aminoanthracene

3.* : The growth of background bacteria on the plate was apparently inhibited compared to the negative control.

**: The growth of background bacteria on the plate was inhibited by the test substance, resulting in their death with

small colonies as observed with the naked eye.

***: The growth of background bacteria on the plate was strongly inhibited by the test substance, resulting in their death and the absence of small colonies.

Conclusions:
Interpretation of results (migrated information):
negative with metabolic activation
negative without metabolic activation

It was concluded that MODA does not show mutagenic potential under the conditions of the present study regardless of the presence or absence of metabolic activation.
Executive summary:

A reverse mutation study of 2-methyl-1,8-octanediamine (MODA) was conducted at Shin Nippon Biomedical Laboratories, Ltd., Japan, by the plate method using the following five strains in order to evaluate the mutagenic potential of MODA: Salmonella typhimurium TA98, TA100, TA1535 and TA1537 and Escherichia coli WP2urvA. The study was conducted according to the Japanese Guidelines:

i. Kanpogyo Notification No. 700, Yakuhatsu Notification No. 1039, (issued jointly with 61 Kikyoku Notification No. 1014) and

ii. Article 57-2 of the Industrial Safety and Health Law (Act No. 57 of 1972) (Ministry of Labor Notice No. 77 of September 1, 1988).

The study was also conducted according to the principles of GLP. Seven different doses of the test substance, ranging between 5 and 5,000 µg/plate with a common ratio of about 3, were used in the dose-ranging study regardless of whether metabolic activation was conducted. Six different doses of the test substance, ranging between 156 and 5,000 µg/plate with a common ratio of about 2, were used in the main study regardless of whether metabolic activation was conducted. MODA did not cause 2-folds or greater increases in the revertant colony count for any of the five strains compared to the negative control regardless of the presence or absence of metabolic activation in either the dose-ranging study or the main study. In the absence of metabolic activation, the growth of TA100, TA1535 and TA1537 was inhibited at 2,500 µg/plate or higher concentrations, while that of WP2urvA and TA98 was inhibited at 5,000 µg/plate.

In the presence of metabolic activation, the growth of TA100, TA1535, TA98, and TA1537 was inhibited at 5,000 µg/plate. The test substance did not precipitate up to 5,000 µg/plate regardless of the presence or absence of metabolic activation.

The number of revertant colonies was within the reference range of this laboratory in both the negative control group and positive control groups, indicating that this study was conducted under appropriate conditions. Based on these findings, it was concluded that MODA does not show mutagenic potential under the conditions of the present study regardless of the presence or absence of metabolic activation.

Endpoint:
in vitro cytogenicity / micronucleus study
Remarks:
Type of genotoxicity: chromosome aberration
Type of information:
experimental study
Adequacy of study:
weight of evidence
Study period:
2015-01-19 to 2015-03-24
Reliability:
1 (reliable without restriction)
Qualifier:
according to guideline
Guideline:
other: OECD 487 in vitro mammalian cell micronucleus test (26 September 2014)
GLP compliance:
yes (incl. QA statement)
Type of assay:
in vitro mammalian cell micronucleus test
Species / strain / cell type:
lymphocytes: human peripheral blood lymphocytes
Details on mammalian cell type (if applicable):
- Blood samples were obtained by venapuncture from young healthy, non-smoking individuals (24 and 34 years old) with no known recent exposures to genotoxic chemicals or radiation
- Type and identity of media: The medium for culturing the human peripheral blood lymphocytes consisted of RPMI 1640 medium (with HEPES and Glutamax), supplemented with heatinactivated (30 min, 56ºC) foetal calf serum (20%), penicillin (100 U/ml medium), streptomycin (100 µg/ml medium) and phytohaemagglutinin (2.4 µg/ml)
Additional strain / cell type characteristics:
not applicable
Metabolic activation:
with and without
Metabolic activation system:
S9 mix
Test concentrations with justification for top dose:
Experiment 1: 1266, 633, 317, 158, 79, 40, 20, 10, 5, 2.5 µg/mL (pulse treatment method with and without metabolic activation)
Experiment 2: 1266, 886, 620, 434, 303, 213 µg/mL (pulse treatment method without metabolic activation)
Experiment 2: 1266, 886, 620, 434, 303, 213, 149, 104, 72.8, 51.1, 35.8, 25.0, 17.5, 12.3 µg/mL (continuous treatment method without metabolic activation)
Vehicle / solvent:
- Vehicle(s)/solvent(s) used: RPMI 1640 medium
Untreated negative controls:
no
Negative solvent / vehicle controls:
yes
Remarks:
culture medium
Positive controls:
yes
Positive control substance:
cyclophosphamide
other: vinblastine sulphate
Details on test system and experimental conditions:
METHOD OF APPLICATION: in medium

DURATION
- Preincubation period: experiment 1 and 2: 48 hours
- Exposure duration and Expression time: experiment 1: 4 hours treatment time and 20 hours recovery time; experiment 2: 24 hours treatment time
- Selection time (if incubation with a selection agent): experiment 1 and experiment 2 (pulse treatment method): 20 hours (during recovery time); experiment 2 (continuous treatment method): 24 hours (during treatment time)
- Fixation time (start of exposure up to fixation or harvest of cells): 72 hours (at the end of the total incubation period)

SELECTION AGENT (mutation assays): cytochalasin B
STAIN (for cytogenetic assays): acridin-orange

NUMBER OF REPLICATIONS: 2

NUMBER OF CELLS EVALUATED: 500 cells per slide (in total 1000 cells per dose level)

DETERMINATION OF CYTOTOXICITY
- Method: Cytokinesis-Block Proliferation Index (CBPI)

Evaluation criteria:
The frequencies of binucleated cells with micronuclei were used for the evaluation of micronuclei induction. The CBPI was calculated for treated (selected doses) and control cultures as a measure of cell cycle delay. If observed, the concurrent measures of cytotoxicity (cell density on the slides, signs of apoptosis or necrosis) were recorded for all treated and negative control cultures.
The study was considered valid if the clastogenic and aneugenic positive controls gave a statistically significant increase in the number of binucleated cells containing micronuclei and if the negative controls (culture medium) were within the historical data performed at the test facility.
A response was considered positive if a statistically significant concentration-related or a reproducible statistically significant increase in the number of binucleated cells containing micronuclei was induced, at any of the test points. The biological relevance will be considered first. During evaluation, the observed values will be compared with the historical control range. Statistical methods will be used as an aid in evaluating the test results but will not be the only determining factor for a positive response. However, the results of statistical testing will be assessed with respect to dose-response relationship.
A response was considered equivocal if the percentage of binucleated cells containing micronuclei was marginally statistically significant higher than that of the negative control (0.05A test substance was considered negative if it produces neither a statistically significant concentration-related nor a reproducible statistically significant increase in the number of binucleated cells containing micronuclei, at any of the test points.
Statistics:
Chi-square test (one-sided):
The frequencies of micronuclei found in the cultures treated with the test substance and positive control cultures were compared with those of the concurrent negative control using the Chi-square test (one-sided). The results were considered statistically significant when the p-value of the Chi-square test was less than 0.05.
Species / strain:
lymphocytes: human peripheral blood lymphocytes
Metabolic activation:
with and without
Genotoxicity:
negative
Cytotoxicity / choice of top concentrations:
cytotoxicity
Vehicle controls validity:
valid
Positive controls validity:
valid
Additional information on results:
TEST-SPECIFIC CONFOUNDING FACTORS
- Effects of pH: up to the testet concentration of 1266 µg/mL the pH of the cultures was not changed by more than 1 pH unit when compared to the solvent control.
- Cultures were slightly haemolytic at the concentration of 1266 µg/mL in experiment 1 without metabolic actiovation and experiment 2 continuous treatment without metabolic activation

COMPARISON WITH HISTORICAL CONTROL DATA: yes

ADDITIONAL INFORMATION ON CYTOTOXICITY:
- Due to a steep concentration response curve for the cytotoxicity of the test substance, concentrations achieving the moderate toxicity level were not obtained and therefore this group was repeated in the second experiment simultaneously with the continuous treatment group.
- In the pulse treatment groups both with and without metabolic activation (S9-mix), at the highest concentration (1266 µg/ml) a low cell density on the slides was observed indicating cell death in the cultures. As a result, the calculated cytotoxicity from the CBPI values may be an underestimation of the actual cytotoxicity
- In the second experiment, in the pulse treatment group without metabolic activation, at the highest concentration of 1266 µg/ml, the cell density on the slides was very low. The calculated cytotoxicity of 1% was therefore considered an underestimation of the actual cytotoxicity
Remarks on result:
other: all strains/cell types tested
Remarks:
Migrated from field 'Test system'.

- Micronuclei induction as a result of treatment with the negative control and the positive controls:

In both the first and second experiment, the negative control (culture medium) was within the range of historical data of the test facility, except for the continuous treatment group, were the number of micronuclei found in the binucleated cells was slightly below the lower end of the historical range. As the observed low frequency of the micronuclei in this group may be the result of inter individual variation in the blood donors and the result is only marginally below the range, the experiment is still considered valid.

- Micronuclei induction as a result of treatment with the test substance: In the first experiment, in the pulse treatment groups both with and without

metabolic activation, three dose levels of the test substance (1266, 633 and 317 µg/mL), together with the solvent control (culture medium) and

positive control, were analyzed for micronucleus induction in binucleated lymphocytes.

In the pulse treatment group with metabolic activation, the highest concentration of the test substance resulted in a statistically marginally higher (p = 0.0841) increase in the number of binucleated cells containing micronuclei, when compared to the numbers found in the concurrent control cultures (Table 1). However, the number of binucleated cells containing micronuclei for this concentration was equal to the upper level of the historical control range and considering the fact that this concentration induced an increase in pH of (almost) one unit, this result is considered to be a matter of chance and not biologically relevant.

In the pulse treatment group without metabolic activation, the test substance did not show a statistically significant increase in the number of binucleated cells containing micronuclei, at any of the concentrations analysed when compared to the numbers found in the concurrent control cultures (Table 2).

In the second experiment, in the pulse treatment group without metabolic activation, the highest concentration (1266 µg/ml) was not selected for analysis of micronuclei induction in binucleated cells due to the low cell density on the slides (indicating severe cytotoxicity). Three dose levels of the test substance (886, 434 and 213 µg/mL), together with the solvent control (culture medium), were analyzed for micronucleus induction in binucleated lymphocytes.

In the continuous treatment group without metabolic activation, at the concentration of 886 µg/mL, the observed cytotoxicity (65%) was slightly higher than the cytotoxicity (55 ± 5%) as defined in the study plan. Nevertheless, the observed cytotoxicity was close enough to the defined range to be considered acceptable. Therefore, four dose levels of the test substance (886, 620, 303 and 104 µg/mL), together with the solvent control (culture medium) and positive control were analysed for micronucleus induction in binucleated lymphocytes.

In the second experiment, in the pulse treatment group without metabolic activation, the highest concentration (886 µg/mL) of the test substance resulted in a statistically marginally higher (p = 0.0577) increase in the number of binucleated cells containing micronuclei, when compared to the numbers found in the concurrent control cultures (Table 3). However, the number of binucleated cells containing micronuclei for this concentration was well within the historical control range. In addition, in the first experiment in the pulse treatment group without metabolic activation, no increase was observed when tested up to the highest feasible concentration of 1266 µg/mL. Hence, this result is not reproducible and thus considered to be a matter of chance and not biologically relevant.

In the continuous treatment group without metabolic activation, at the lowest concentration analysed (104 µg/mL), the test substance showed a statistically marginally higher (p = 0.0537) increase in the number of binucleated cells containing micronuclei, when compared to the numbers found in the concurrent control cultures (Table 4). However, the three higher concentrations analysed did not show an increase in the number of binucleated cells containing micronuclei. Hence, the response was not dose related. In addition, the response observed for this concentration was well within the historical range and the number of micronuclei found in the concurrent solvent control was slightly below the lower end of the historical data. Therefore, this result is considered to be a matter of chance and not biological relevant.

Table 1: Experiment 1 – Pulse treatment method with metabolic activation (S9-mix)

Treatm/recovery time (h)

Dose level (µg/mL)

Cell stage analysis/500 (MO-BN-MU)

BN (%)

CBPI

CBPI (mean)

RI (%)

% Cytotox. (100-RI)

Selected for MN analysis (+/-)

MNBN/1000BN

MNBN/2000BN (%)

Statistics 1) (p-value)

4/20 (+S9)

NC

227 267 6

53.40

1.56

1.55

100

0

+

6/1000

13/2000

-

 

233 261 6

52.20

1.55

 

 

 

 

7/1000

0.65

 

1266

332 168 0

33.60

1.34

1.31

57

43

+

13/1000

21/2000

0.0841

 

357 142 1

28.40

1.29

 

 

 

 

8/1000

1.05

 

633

265 232 3

46.40

1.48

1.47

86

14

+

9/1000

13/2000

n.s.

 

270 224 6

44.80

1.47

 

 

 

 

4/1000

0.65

 

317

260 234 6

46.80

1.49

1.51

91

9

+

9/1000

15/2000

n.s.

 

245 251 4

50.20

1.52

 

 

 

 

6/1000

0.75

 

158

240 254 6

50.80

1.53

1.55

100

0

-

-

-

-

 

221 272 7

54.40

1.57

 

 

 

 

-

 

 

79

255 243 5

48.31

1.50

1.52

94

6

-

-

-

-

 

242 250 8

50.00

1.53

 

 

 

 

-

 

 

40

264 231 5

46.20

1.48

1.50

90

10

-

-

-

-

 

253 240 7

48.00

1.51

 

 

 

 

-

 

 

CP25

372 127 1

25.40

1.26

1.27

48

52

+

32/1000

66/2000

<0.0001

 

363 136 1

27.20

1.28

 

 

 

 

34/1000

3.30

***

The fixed cells of the other dose levels (2.5 to 20 µg/mL) were stored without slide preparation

Table 2: Experiment 1 – Pulse treatment method without metabolic activation (S9-mix)

Treatm/recovery time (h)

Dose level (µg/mL)

Cell stage analysis/500 (MO-BN-MU)

BN (%)

CBPI

CBPI (mean)

RI (%)

% Cytotox. (100-RI)

Selected for MN analysis (+/-)

MNBN/1000BN

MNBN/2000BN (%)

Statistics 1) (p-value)

4/20 (-S9)

NC

224 267 9

53.40

1.57

1.56

100

0

+

6/1000

12/2000

-

 

232 259 9

51.80

1.55

 

 

 

 

6/1000

(0.60)

 

1266

348 149 3

29.80

1.31

1.32

56

44

+

11/1000

16/2000

n.s

 

344 156 3

31.01

1.32

 

 

 

 

5/1000

(0.80)

 

633

229 265 6

53.00

1.55

1.55

98

2

+

3/1000

10/2000

n.s.

 

237 255 8

51.00

1.54

 

 

 

 

7/1000

(0.50)

 

317

224 269 7

53.80

1.57

1.55

98

2

+

6/1000

12/2000

n.s.

 

239 256 5

51.20

1.53

 

 

 

 

6/1000

(0.60)

 

158

251 239 10

47.80

1.52

1.51

91

9

-

-

-

-

 

254 242 4

48.40

1.50

 

 

 

 

-

 

 

79

245 251 4

50.20

1.52

1.49

88

12

-

-

-

-

 

277 218 10

43.17

1.47

 

 

 

 

-

 

 

40

231 259 10

51.80

1.56

1.55

98

2

-

-

-

-

 

234 258 8

51.60

1.55

 

 

 

 

-

 

 

The fixed cells of the other dose levels (2.5 to 20 µg/mL) were stored without slide preparation

Results to be continued in section "Overall remarks, attachements"

Conclusions:
Interpretation of results (migrated information):
negative

From the results obtained in the in vitro micronucleus test it is concluded that, under the conditions used in this study, the test substance, MODA, was not clastogenic and/or aneugenic to cultured human lymphocytes.
Endpoint conclusion
Endpoint conclusion:
no adverse effect observed (negative)

Genetic toxicity in vivo

Description of key information

weight of evidence approach based on in vitro data and QSAR predictions

Link to relevant study records
Reference
Endpoint:
genetic toxicity in vivo, other
Data waiving:
study scientifically not necessary / other information available
Justification for data waiving:
other:
Justification for type of information:
WoE approach determines a negative result overall for in vitro mutagenicity. It was concluded that the positive effects seen in the Chromosomal aberration test (1997) were generated at highly cytotoxic doses and should be interpreted with caution. A micronucleus study (2015) was conducted using an appropriate concentration range and with the determination of the cytotoxicity simultaneously during the main study. The results of this study were negative. These results were supported by three QSAR studies which all had negative results for genotoxicity.
Reason / purpose for cross-reference:
data waiving: supporting information
Endpoint conclusion
Endpoint conclusion:
no adverse effect observed (negative)

Additional information

Additional information from genetic toxicity in vitro:


Four in vitro genetic toxicity studies are available for the mutagenicity endpoint of MODA and were used for the assessment:


One in vitro gene mutation study in bacteria (Kazuhiko Saigo, 1997;equivalent/similar to OECD 471), one in vitro gene mutation study in mammalian cells (TÜV SÜD, 2012;OECD 476), one chromosome aberration test (Kazuhiko Saigo, 1997;equivalent/similar to OECD 473) with Chinese hamster lung (CHL)/IU) cells and one in vitro micronucleus study (B. Usta, BSc, 2015;OECD 487) with cultured human lymphocytes. Additionally, three QSAR calculations were conducted (OECD Toolbox, Vega and Test).


 


An in vitro gene mutation study in bacteria (Kazuhiko Saigo,1997) was conducted using five bacterial strains (Salmonella typhimurium TA98, TA100, TA1535 and TA1537 and E. coli WP2urvA) to evaluate the mutagenic potential of the substance. Six different doses, 156, 313, 625, 1250, 2500, and 5000µg/plate, were used in the main study with and without metabolic activation. Cytotoxicity was observed at concentrations of 2500 and 5000 µg/plate. In this test, the substance did not show mutagenic potential with and without metabolic activation.


 


In an in vitro mammalian cell gene mutation study using mouse lymphoma L5178Y cells (TÜV SÜD, 2012; OECD 476) cytotoxic effects (cell growth inhibition) were observed at 2.5µg/mL and above concentrations in a pretest. Concentrations of 2.5µg/mL, 1.25µg/mL, 0.625µg/mL and 0.3125µg/mL were used for the main test.  In this test the substance was determined to be non-mutagenic to the L5178Y TK+/- clone, both in the absence and presence of metabolic activation.


 


In the chromosome aberration study using cultured Chinese hamster lung-derived fibroblast cells (Kazuhiko Saigo, 1997) a positive result was concluded for the substance. The test was carried out with 12.5, 25, 50, and 100 µg/mL in the absence of metabolic activation with the treatment periods of 24 and 48 hrs, and with 44.4, 66.7, 100, and 150 µg/mL in the presence of metabolic activation without S9 Mix, and at 444, 667, 1000, and 1500 µg/mL in the presence of metabolic activation with S9 Mix. Doses were set so that the cell survival rate ranged between 20% and 80% based on the results of a range finding study. Cytotoxicity was not evaluated during the main study. Positive results were observed at concentrations of 50 and 100 µg/mL in the absence of metabolic activation with the treatment periods of 24 and 48 hrs. Both concentrations were above the 50% cell growth inhibition concentration (GI50) of around 48 and 35 µg/mL, respectively, as determined in the pretest. With metabolic activation a positive result was observed with S9 Mix at 1000 µg/mL. Here, a GI50 of 610µg/mL was calculated from the range finding study. With metabolic activation without S9 Mix positive results were observed at all four concentrations (44.4, 66.7, 100, and 150 µg/mL). For this method, a GI50 of 80µg/mL was calculated from the range finding study. As most of the positive responses were observed at doses above the GI50 value the study is considered of limited value because the observed chromosome damage may be induced as a secondary effect of cytotoxicity (ECHA guidance R7a, 2015 section R.7.7.4.1). Also cytotoxicity was not determined in the main study but in a separate test.


 


As the positive result of the chromosome aberration test (equivalent/similar to OECD 473) with Chinese hamster lung cells was considered to be questionable a follow up study was carried out to determine the potential for chromosome damaging of the substance. Due to the observed high cytotoxicity in the first chromosome aberration test using Chinese hamster lung cells, the follow up test was conducted with cultured human lymphocytes in a micronucleus test according to OECD 487 (B. Usta, BSc, 2015) with the following concentrations: Experiment 1: 1266, 633, 317, 158, 79, 40, 20, 10, 5, 2.5 µg/mL (pulse treatment method with and without metabolic activation; Experiment 2: 1266, 886, 620, 434, 303, 213 µg/mL (pulse treatment method without metabolic activation); Experiment 2: 1266, 886, 620, 434, 303, 213, 149, 104, 72.8, 51.1, 35.8, 25.0, 17.5, 12.3 µg/mL (continuous treatment method without metabolic activation). In this test the Cytotoxicity was determined from the Cytokinesis-Block Proliferation Index (CBPI) and three test concentrations (not including the solvent and positive controls) that meet the acceptability criteria (appropriate cytotoxicity, number of cells, etc) could be evaluated as required according to the test guideline. From the results obtained in this in vitro micronucleus test it was concluded that, under the reliable conditions used in this study, the test substance MODA was not clastogenic and/or aneugenic to cultured human lymphocytes.


 


In addition three independent QSAR studies were conducted using different models. All three models predict that primary amines do not have a genotoxic potential.


 


The available data were used in a weight of evidence approach to determine the potential of the substance for genetic toxicity. It was concluded that the substance has no mutagenic potential and further in vivo testing was not deemed necessary.



Justification for selection of genetic toxicity endpoint
The mammalian cell micronucleus test (OECD 487) is the most recent study.

Justification for classification or non-classification

Not classified. The data indicate that MODA is not genotoxic.